Phospho-GRIN1 (S890) Antibody

What is the Phospho-GRIN1 (S890) antibody and what epitope does it recognize?

The Phospho-GRIN1 (S890) antibody is a polyclonal antibody specifically designed to detect GRIN1 (glutamate receptor ionotropic NMDA 1) only when phosphorylated at serine 890. These antibodies are typically raised in rabbits using synthetic phosphorylated peptides corresponding to residues surrounding S890 of human GRIN1 as immunogens . The recognized epitope consists of a specific amino acid sequence (e.g., A-S-SP-F-K) where the serine residue at position 890 is phosphorylated . This specificity makes the antibody valuable for studying phosphorylation-dependent regulation of NMDA receptor function in neuronal signaling pathways.

Most commercially available Phospho-GRIN1 (S890) antibodies demonstrate cross-reactivity with multiple species due to the high conservation of the phosphorylation site. The confirmed species reactivity includes:

• Human

• Mouse

• Rat

The antibodies are typically validated using cell lines such as C6 rat glioma cells treated with PMA/TPA (200nM) to induce phosphorylation . When working with less common species, researchers should conduct preliminary validation experiments, as the degree of conservation at this epitope may affect antibody performance.

What is the functional significance of GRIN1 S890 phosphorylation in neuronal signaling?

The phosphorylation of GRIN1 at S890 plays a critical role in regulating NMDA receptor function and trafficking. Research has demonstrated that:

• S890 phosphorylation influences receptor clustering and surface expression, affecting synaptic localization of NMDARs

• This site is phosphorylated by PKC (Protein Kinase C) in response to various stimuli, including PMA/TPA treatment

• The phosphorylation state of S890 can affect channel kinetics and conductance properties of the NMDAR complex

• It contributes to synaptic plasticity mechanisms underlying learning and memory formation

In studies using phosphomimetic (S890D) and phosphodeficient (S890A) mutants, researchers have demonstrated that this phosphorylation event regulates the C-terminal interactions of GRIN1 with intracellular proteins, thereby modulating its subcellular trafficking and function .

How does GRIN1 S890 phosphorylation differ from other phosphorylation sites on NMDA receptor subunits?

GRIN1 contains multiple phosphorylation sites with distinct regulatory roles:

Unlike GRIN2A S882/S890, which becomes hyper-phosphorylated under neurogranin knockdown conditions, GRIN1 S890 phosphorylation responds differently to neuronal activity and intracellular signaling events . This site-specific phosphorylation pattern is critical for understanding the complex regulation of NMDA receptor function in neuronal plasticity and pathological conditions.

What are the critical controls needed when using Phospho-GRIN1 (S890) antibodies in Western blot applications?

When using Phospho-GRIN1 (S890) antibodies in Western blot experiments, researchers should include these critical controls:

• Phosphatase treatment control: Treat sample aliquots with lambda phosphatase to demonstrate specificity for the phosphorylated form

• Phosphorylation induction control: Include samples from cells treated with PKC activators like PMA/TPA (200nM for 30 minutes) after serum starvation overnight

• Blocking peptide competition: Pre-incubate antibody with the phosphorylated peptide immunogen to confirm binding specificity

• Total GRIN1 detection: Parallel blots with antibodies recognizing total GRIN1 (phosphorylation-independent) to normalize phospho-signal

• Loading controls: Standard housekeeping proteins (e.g., β-actin, GAPDH) to ensure equal loading

• Molecular weight verification: GRIN1 should be detected at approximately 105-140 kDa depending on post-translational modifications

How should samples be prepared to preserve GRIN1 phosphorylation for antibody detection?

Sample preparation is critical for preserving phosphorylation states:

• Rapid tissue collection: Minimize post-mortem interval to prevent dephosphorylation

• Phosphatase inhibitor cocktail: Include in all buffers (e.g., RIPA buffer supplemented with sodium orthovanadate, sodium fluoride, β-glycerophosphate)

• Temperature control: Keep samples cold (0-4°C) during preparation

• Denaturing conditions: Use strong denaturing buffers containing SDS to inactivate endogenous phosphatases

• Protein extraction optimization: For membrane proteins like GRIN1, consider specialized extraction methods that maintain native conformation while preserving phosphorylation

• Storage considerations: Aliquot samples and store at -80°C, avoiding repeated freeze-thaw cycles

For cell culture models, perform serum starvation followed by stimulation with PKC activators like PMA/TPA (200nM) for 30 minutes to enhance S890 phosphorylation before lysis . This approach increases signal-to-noise ratio when detecting phosphorylated forms.

How can researchers address non-specific binding issues with Phospho-GRIN1 (S890) antibodies?

Non-specific binding can compromise experimental results. To address this issue:

• Optimize blocking conditions: Test different blocking agents (BSA, milk, commercial blockers) at various concentrations (3-5%)

• Adjust antibody dilution: Titrate the antibody concentration (1:500-1:2000 for WB) to find optimal signal-to-noise ratio

• Increase washing stringency: Use detergent-containing (0.1% Tween-20) wash buffers and extend washing times

• Pre-absorb antibody: Incubate with non-phosphorylated peptide to remove antibodies that recognize non-phosphorylated epitopes

• Use peptide competition: Include a gradient of competing phospho-peptide to demonstrate signal specificity

• Secondary antibody controls: Include controls with secondary antibody only to identify non-specific binding

Methodology note: When performing immunohistochemistry, tissue-specific autofluorescence can be reduced using Sudan Black B treatment (0.1-0.3% in 70% ethanol) or specialized commercial reagents designed to reduce background in neural tissues.

What are the best approaches for quantifying changes in GRIN1 S890 phosphorylation levels?

For reliable quantification of GRIN1 S890 phosphorylation:

• Normalization strategy: Always normalize phospho-signal to total GRIN1 levels detected in parallel samples

• Technical replicates: Include at least three technical replicates per biological sample

• Standard curve: When possible, include a dilution series of a standardized sample to ensure quantification in the linear range

• Image acquisition: Use linear detection methods (avoid saturated signals) with appropriate exposure times

• Quantification software: Employ specialized software (ImageJ, Image Lab, etc.) with consistent region-of-interest selection

• Statistical analysis: Apply appropriate statistical tests based on experimental design and data distribution

For more precise quantification in complex samples, consider phospho-enrichment methods prior to analysis or the use of Phos-Tag gels to separate different phosphorylation states .

How can Phospho-GRIN1 (S890) antibodies be utilized in studying neurological disorders associated with NMDA receptor dysfunction?

GRIN1 mutations and dysregulation have been implicated in various neurological disorders including epilepsy, intellectual disability, autism spectrum disorders, and schizophrenia . Phospho-GRIN1 (S890) antibodies can be employed in these research contexts through:

• Patient sample analysis: Compare phosphorylation levels in post-mortem brain tissue between patients and controls

• Animal models: Evaluate receptor phosphorylation in genetic models of neurological disorders

• Drug screening: Assess compounds that modulate NMDA receptor phosphorylation as potential therapeutics

• Cellular phenotyping: Combine with electrophysiology to correlate phosphorylation state with channel function

• Brain region mapping: Use immunohistochemistry to map regional differences in phosphorylation patterns in disease models

Research has revealed that individuals with GRIN1 variants present with distinct phenotypes including profound developmental delay, severe intellectual disability, muscular hypotonia, hyperkinetic movement disorders, and epilepsy . Studying phosphorylation patterns at S890 and other regulatory sites may provide insights into pathological mechanisms and potential treatment strategies.

What methodological approaches can be used to correlate GRIN1 S890 phosphorylation with NMDA receptor electrophysiological properties?

To establish relationships between phosphorylation status and functional properties:

• Site-directed mutagenesis: Generate phosphomimetic (S890D/E) and phosphodeficient (S890A) mutants for functional studies

• Heterologous expression systems: Express wild-type or mutant GRIN1 with GluN2 subunits in Xenopus oocytes or HEK293 cells for electrophysiological recordings

• Single-channel recordings: Analyze channel open probability, conductance, and kinetics in relation to phosphorylation state

• Calcium imaging: Combine with phosphorylation detection to correlate calcium influx with receptor modification

• Pharmacological manipulation: Use kinase activators/inhibitors to modulate phosphorylation during recordings

• High-throughput patch clamp: Employ platforms like SyncroPatch for systematic evaluation of mutants with altered phosphorylation sites

Research has shown that phosphorylation of NMDA receptor subunits influences channel kinetics , with mutations in GRIN1 affecting agonist potency, sensitivity to Mg²⁺ inhibition, and channel open probability . These methodological approaches can help establish causal relationships between specific phosphorylation events and functional outcomes.

How might single-cell analysis techniques be applied to study cell-specific variations in GRIN1 S890 phosphorylation?

Emerging single-cell approaches offer new opportunities to study GRIN1 phosphorylation:

• Single-cell phosphoproteomics: Adapt mass spectrometry methods to analyze phosphorylation states in individual neurons

• Proximity ligation assays: Detect phosphorylated GRIN1 in situ with subcellular resolution

• FRET-based sensors: Develop reporters to monitor S890 phosphorylation dynamics in living cells

• Multiplexed immunofluorescence: Combine with cell-type markers to map phosphorylation across neuronal populations

• Spatial transcriptomics: Correlate phosphorylation patterns with local gene expression profiles

• Microfluidic neuronal cultures: Isolate specific neuronal populations for targeted phosphorylation analysis

These approaches would allow researchers to address important questions about cell-type specific regulation of NMDA receptors in complex neural circuits and how this contributes to normal and pathological brain function.

What are the most promising therapeutic strategies targeting GRIN1 phosphorylation in neurological disorders?

Research on GRIN1 phosphorylation has revealed potential therapeutic strategies:

• Kinase modulators: Compounds targeting PKC activity to regulate S890 phosphorylation

• Allosteric modulators: Drugs that stabilize specific receptor conformations associated with phosphorylation states

• Chaperone-mediated trafficking: Interventions affecting receptor surface expression influenced by phosphorylation

• NMDAR channel blockers: FDA-approved drugs like memantine that have shown efficacy in treating seizures in patients with GRIN1 mutations

• Precision medicine approaches: Tailoring treatments based on specific genetic variants and resulting phosphorylation profiles

For example, a case study of a patient with a GRIN1 mutation (Met641Ile) and early-onset epileptic encephalopathy showed that memantine treatment significantly reduced seizure burden . Understanding the relationship between mutation-specific effects on phosphorylation and channel function could lead to more personalized treatment approaches for GRIN1-related neurological conditions.